Abstract Library

#3259 Treatment outcomes of patients with G3 neuroendocrine neoplasms

Introduction: Extrapulmonary neuroendocrine carcinomas (NEC) and neuroendocrine tumors (NET) G3 are aggressive neoplasia that are associated with a limited prognosis.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Roderburg C

Authors: Jann H, Wiedenmann B, Tacke F, Roderburg C,

Keywords: NEN G3, chemotherapy, Cisplatin, Carboplatin,

#3244 Efficacy and safety of immune checkpoint inhibitors in patients with neuroendocrine neoplasia: Report of a case series from a large tertiary centre

Introduction: Immune checkpoint inhibitors (ICI) have changed our view on how to treat cancer. Despite their approved treatment of many different cancers, efficacy of ICI in neuroendocrine neoplasia is limited and poorly understood. Established treatment options of neuroendocrine tumors (NET) and carcinomas (NEC) are based on surgery, tumor-targeted medical treatments, peptide guided radioreceptor therapy (PRRT) and locoregional therapies. However, in many patients these treatments lose efficacy over time, and novel therapies are urgently needed.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Roderburg C

Authors: Özdirik B, Jann H, Tacke F, Wiedenmann B, Roderburg C,

Keywords: checkpoint inhibitor, neuroendocrine neoplasia, PD-L1,

#3240 miR-29b serum levels are down-regulated in patients with neuroendocrine tumors

Introduction: Due to its involvement in tumor biology as well as tumor-associated stroma cell responses, recent data suggested a potential role of miR-29 as a biomarker for different malignancies.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Roderburg C

Authors: Özdirik B, Mohr R, Jann H, Geisler L, Tacke F,

Keywords: neuroendocrine tumor, miRNA, miR-29, prognosis, biomarker,

#3237 Soluble urokinase Plasminogen Activator Receptor (suPAR) serum levels are elevated in patients with neuroendocrine neoplasia

Introduction: Neuroendocrine neoplasia (NEN) represent a heterogeneous group of malignancies that might be challenging to diagnose. In case of advanced disease stages and especially in cases of poorly differentiated (G3) NEN, patients face a dismal prognosis. Therefore, innovative biomarkers allowing an early diagnosis as well as an optimal selection of suitable treatment options might help to improve clinical management of these patients.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Roderburg C

Authors: Burcin �, Mohr R, Jann H, Geisler L, Tacke F,

Keywords: suPAR, neuroendocrine tumor, biomarker, prognosis,

#3195 Peptide Radio Receptor Therapy sensitizes to immunotherapy by increasing expression of checkpoint molecules in in patients with neuroendocrine tumors

Introduction: Peptide Radio Receptor Therapy (PRRT) represents a standard treatment in patients with well-differentiated neuroendocrine tumors (NET G1/G2). Nevertheless, a lack of response is observed in 1/3 of patients after PRRT, suggesting that combination of PRRT with other therapies might increase its efficacy. The combination of PRRT with immune checkpoint inhibitors (ICI) might be promising, since radiation induced cell death can trigger antigen release and lead to activation of the immune system.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Hammerich L

Authors: Büttne S, Wiedenmann B, Amthauer H, Tacke F, Roderburg C,

Keywords: neuroendocrine tumor, checkpoint blockade, PRRT, immunotherapy, spectral flow cytometry,